Monitoring for HBV treatment response and disease progression. It is recommended that the following be monitored at least annually:

• ALT levels (and AST for APRI), HBsAg, HBeAg, and HBV DNA levels (where HBV

DNA testing is available)

• Non-invasive tests (APRI score or transient elastography) to assess for presence

of cirrhosis in those without cirrhosis at baseline;

• If on treatment, adherence should be monitored regularly and at each visit.